
PolarityTE PTE
Quarterly report 2023-Q1
added 05-12-2023
PolarityTE Total Assets 2011-2026 | PTE
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets PolarityTE
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22.8 M | 31.2 M | 45.5 M | 53.6 M | 87.8 M | 20.2 M | 6.75 M | 17.7 M | 11.5 M | 37.6 M | 49.3 M | 52.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 87.8 M | 6.75 M | 36.4 M |
Quarterly Total Assets PolarityTE
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18 M | 22.8 M | 22.1 M | 28 M | 30 M | 31.2 M | 41.3 M | 48.4 M | 57.1 M | 45.5 M | 45.5 M | 45.5 M | 45.5 M | 53.6 M | 53.6 M | 53.6 M | 53.6 M | 80.2 M | 80.2 M | 80.2 M | 80.2 M | 8.78 M | 20.2 M | 20.2 M | 20.2 M | 6.75 M | 6.75 M | 6.75 M | 6.75 M | 12.2 M | 17.7 M | 17.7 M | 17.7 M | 25.4 M | 11.5 M | 11.5 M | 11.5 M | 42.7 M | 37.6 M | 37.6 M | 37.6 M | 56.8 M | 49.3 M | 49.3 M | 49.3 M | - | 52.4 M | 52.4 M | 52.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 80.2 M | 6.75 M | 36.6 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
Anika Therapeutics
ANIK
|
271 M | $ 14.93 | 0.88 % | $ 219 M | ||
|
Aptorum Group Limited
APM
|
16.1 M | $ 0.93 | 0.51 % | $ 5.07 M | ||
|
Aquestive Therapeutics
AQST
|
160 M | $ 4.14 | 0.36 % | $ 443 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
271 M | $ 8.39 | 4.5 % | $ 230 M | ||
|
Ardelyx
ARDX
|
502 M | $ 6.06 | 1.94 % | $ 1.46 B | ||
|
argenx SE
ARGX
|
8.68 B | $ 749.68 | 0.44 % | $ 25 B | ||
|
Arcutis Biotherapeutics
ARQT
|
433 M | $ 23.93 | 1.27 % | $ 3.04 B | ||
|
Arvinas
ARVN
|
718 M | $ 11.36 | 4.7 % | $ 805 M | ||
|
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | ||
|
Arrowhead Pharmaceuticals
ARWR
|
1.39 B | $ 61.99 | 1.57 % | $ 8.29 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | ||
|
Assembly Biosciences
ASMB
|
258 M | $ 29.09 | 0.28 % | $ 326 M | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Actinium Pharmaceuticals
ATNM
|
51.8 M | $ 1.13 | 15.26 % | $ 35.3 M | ||
|
Atossa Therapeutics
ATOS
|
47.6 M | $ 5.19 | -3.36 % | $ 44.7 M | ||
|
Atara Biotherapeutics
ATRA
|
20.2 M | $ 5.0 | 0.2 % | $ 62.7 M | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
752 M | $ 16.05 | 2.79 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
589 M | $ 1.41 | -0.35 % | $ 375 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Axon Enterprise
AXON
|
4.47 B | $ 411.97 | -0.2 % | $ 31.2 B | ||
|
Aytu BioScience
AYTU
|
124 M | $ 2.65 | -1.12 % | $ 16.6 M | ||
|
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | ||
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | ||
|
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | ||
|
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | ||
|
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
BioCardia
BCDA
|
3.41 M | $ 1.18 | -1.67 % | $ 7.87 M | ||
|
BioCryst Pharmaceuticals
BCRX
|
490 M | $ 9.59 | 6.26 % | $ 1.98 B | ||
|
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | ||
|
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | ||
|
Aileron Therapeutics
ALRN
|
24.2 M | - | 10.36 % | $ 9.8 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
104 M | $ 3.05 | 1.51 % | $ 260 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.08 B | $ 9.46 | -3.47 % | $ 612 M | ||
|
BioVie
BIVI
|
21.6 M | $ 1.46 | 2.81 % | $ 2.16 M | ||
|
BioLineRx Ltd.
BLRX
|
38.9 M | $ 2.32 | 4.98 % | $ 908 M | ||
|
BioMarin Pharmaceutical
BMRN
|
7.59 B | $ 56.04 | 0.96 % | $ 10.7 B | ||
|
BioNTech SE
BNTX
|
22 B | $ 91.64 | 0.5 % | $ 27.2 B | ||
|
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | ||
|
BioXcel Therapeutics
BTAI
|
44.9 M | $ 1.18 | -0.42 % | $ 14.4 M | ||
|
Burford Capital Limited
BUR
|
3.11 B | $ 4.5 | 8.57 % | $ 683 M |